---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-077369"
form_type: "8-K"
ticker: "CPHI"
cik: "0001106644"
company_name: "CHINA PHARMA HOLDINGS, INC."
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:04:48.086225+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# China Pharma subsidiary acquires ophthalmic oxygen therapy patent rights for $2.1M in stock

## Summary
- Hainan Helpson acquires utility model patent (ZL 2022 2 0394857.6) and invention patent application for ophthalmic oxygen enriched atomization device from Chengdu Bonier.
- Transfer price: RMB 15M (~$2.1M) paid via 11.1M CPHI shares at $0.1349/share within 10 days under Regulation S exemption.
- Bonier provides 10-year technical services including product R&D, registration, and must secure Class II medical device registration within one year.
- Service fee: 15% of net profit from product sales annually for 10 years, contingent on invention patent grant; if not granted, no service fee owed.
- Stock issuance is unregistered and exempt under Regulation S; shares to a non-U.S. person in an offshore transaction.

## SEC filing metadata
- accession: 0001213900-22-077369
- form_type: 8-K
- ticker: CPHI
- cik: 0001106644
- company_name: CHINA PHARMA HOLDINGS, INC.
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/0001213900-22-077369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/ea169540-8k_chinapharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-077369
- JSON: https://secwatch.observer/filing/0001213900-22-077369.json
- Plain text: https://secwatch.observer/filing/0001213900-22-077369.txt

## Key facts
- Material Agreements
  CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Contract with Chengdu Bonier Medical Technology Development Co., Ltd valued at RMB 15 million, approximately $2.1 million (effective 2022-11-28).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Chengdu Bonier Medical Technology Development Co., Ltd
  - Value: RMB 15 million, approximately $2.1 million
  - Effective: 2022-11-28
  source text: On November 28, 2022, Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “Company”), entered into a Technology Transfer Contract (the “Agreement”) with Chengdu Bonier Medical Technology Development Co., Ltd (“Bonier”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/0001213900-22-077369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.